References
- Saag MS, Graybill RJ, Larsen RA, . Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:710–718.
- Walsh TJ, Hiemenz JW, Seibel NL, . Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998; 26:1383–1396.
- Pitisuttithum P, Negroni R, Graybill JR, . Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005; 56:745–755.
- Perfect JR, Marr KA, Walsh TJ, . Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003; 36:1122–1131.
- Pappas PG, Bustamante B, Ticona E, . Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis. 2004; 189:2185–2191.
- Thompson GR III, Wiederhold NP, Fothergill AW, . Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother. 2009; 53:309–311.
- Smith J, Safdar N, Knasinski V, . Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006; 50:1570–1572.
- Park BJ, Wannemuehler KA, Marston BJ, . Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009; 23:525–530.
- Thompson GR III, Rinaldi MG, Pennick G, . Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother. 2009; 53:2223–2224.
- Posaconazole FDA Briefing Document. Accessed 17 February 2009 from: http://www.fda.gov/cder/foi/nda/2006/022003s000_Noxafil-TOC.htm
- Pfaller MA, Messer SA, Boyken L, . Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol. 2005; 43:2163–2167.
- Trifilio S, Pennick G, Pi J, . Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007; 109:1532–1535.
- Liu P, Foster G, Gandelman K, . Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother. 2007; 51:3617–3626.
- Pascual A, Calandra T, Bolay S, . Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008; 46:201–211.
- Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006; 136:739–742.
- Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006; 46:235–243.
- Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003; 37:728–732.
- Schwartz S, Ruhnke M, Ribaud P, . Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005; 106:2641–2645.
- Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis. 1998; 26:1266–1269.
- Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother. 2000; 46:437–142.